IMP4

Across TCGA pan-cancer cohorts, IMP4 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated IMP4 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher IMP4 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated IMP4 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

CCRCC, PDAC, and LSCC are the cancer types where IMP4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.658	0.937	<.001	77	view →
PDAC	OS	Quartile	All	0.379	0.651	.001	21	view →
LSCC	DFS	Median	II,III,IV	0.815	0.567	.038	2	view →
LUAD	OS	Median	All	0.717	1.000	.035	2	view →
HNSC	DFS	Median	III,IV	0.932	1.000	.023	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

IMP4–CCRCC (DFS)

Open the CCRCC breakdown →